Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital

We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n=50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n=44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n=23, 14.7%), ALCL ALK positive (n=16, 10.3%), and other (n=23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI)2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p=.001) and OS (p=.046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.